Should I buy or sell Atai Life Sciences stock right now?

3 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Atai Life Sciences in the last twelve months. There are currently 3 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" ATAI shares. View ATAI analyst ratings or view top-rated stocks .

What is Atai Life Sciences' stock price target for 2024?

3 Wall Street analysts have issued 1-year target prices for Atai Life Sciences' stock. Their ATAI share price targets range from $6.00 to $15.00. On average, they anticipate the company's stock price to reach $10.50 in the next twelve months. This suggests a possible upside of 449.7% from the stock's current price. View analysts price targets for ATAI or view top-rated stocks among Wall Street analysts .

How have ATAI shares performed in 2024?

Atai Life Sciences' stock was trading at $1.41 at the start of the year. Since then, ATAI stock has increased by 35.5% and is now trading at $1.91. View the best growth stocks for 2024 here .

Are investors shorting Atai Life Sciences?

Atai Life Sciences saw a increase in short interest in March. As of March 31st, there was short interest totaling 5,550,000 shares, an increase of 6.5% from the March 15th total of 5,210,000 shares. Based on an average daily volume of 1,740,000 shares, the short-interest ratio is presently 3.2 days. Approximately 4.8% of the company's shares are sold short. View Atai Life Sciences' Short Interest .

When is Atai Life Sciences' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, May 9th 2024. View our ATAI earnings forecast .

How were Atai Life Sciences' earnings last quarter?

Atai Life Sciences (NASDAQ:ATAI) posted its quarterly earnings data on Thursday, August, 10th. The company reported ($0.21) earnings per share (EPS) for the quarter, meeting the consensus estimate of ($0.21). The company had revenue of $0.17 million for the quarter. Atai Life Sciences had a negative net margin of 12,810.51% and a negative trailing twelve-month return on equity of 45.08%.

What ETF holds Atai Life Sciences' stock?

AdvisorShares Psychedelics ETF holds 187,558 shares of ATAI stock, representing 5.86% of its portfolio.

What other stocks do shareholders of Atai Life Sciences own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Atai Life Sciences investors own include Alphabet (GOOG) , Baidu (BIDU) , Costco Wholesale (COST) , MannKind (MNKD) , NVIDIA (NVDA) , Schlumberger (SLB) , Twitter (TWTR) , Adobe (ADBE) , Allergan (AGN) and Achaogen (AKAO) .

When did Atai Life Sciences IPO?

Atai Life Sciences (ATAI) raised $200 million in an initial public offering on Friday, June 18th 2021. The company issued 14,300,000 shares at a price of $13.00-$15.00 per share. Credit Suisse, Citigroup, Cowen and Berenberg acted as the underwriters for the IPO and Cantor, RBC Capital Markets and Canaccord Genuity were co-managers.

Who are Atai Life Sciences' major shareholders?

Atai Life Sciences' stock is owned by many different institutional and retail investors. Top institutional investors include Quattro Financial Advisors LLC (0.04%), Kingswood Wealth Advisors LLC (0.02%) and CRA Financial Services LLC (0.01%). Insiders that own company stock include Anne Nagengast Johnson, Apeiron Investment Group Ltd, Christian Angermayer , Florian Brand, Gregory L Weaver and Srinivas Rao . View institutional ownership trends .

How do I buy shares of Atai Life Sciences?

Shares of ATAI stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here .

NASDAQ:ATAI

Atai Life Sciences (ATAI) Stock Price, News & Analysis

→ Biden’s $374B Giveaway Into This Sector (From DTI) (Ad)

Free ATAI Stock Alerts

$1.91

-0.07 (-3.54%)

(As of 04/18/2024 ET)

Compare

Today's Range: $1.91
▼
$2.04
50-Day Range: $1.63
▼
$2.60
52-Week Range: $1.03
▼
$2.85

Volume: 1.02 million shs
Average Volume: 1.76 million shs
Market Capitalization: $317.12 million

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: $10.50

Get Atai Life Sciences alerts:

Atai Life Sciences MarketRank™ Stock Analysis

Analyst Rating: Buy
3.00 Rating Score
Upside/Downside: 449.7% Upside
$10.50 Price Target
Short Interest: Healthy
4.81% of Float Sold Short
Dividend Strength: N/A
Sustainability: N/A
News Sentiment: 0.81
Based on 6 Articles This Week
Insider Trading: Selling Shares
$164,742 Sold Last Quarter
Proj. Earnings Growth: Growing
From ($0.80) to ($0.77) Per Share

Overall MarketRank^™

New Rank-Based ScoringMarketRank^™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

2.96 out of 5 stars

Medical Sector

367th out of 918 stocks

Pharmaceutical Preparations Industry

157th out of 402 stocks

3.5

Analyst's Opinion

Consensus Rating
Atai Life Sciences has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 3 buy ratings, no hold ratings, and no sell ratings.
Amount of Analyst Coverage
Atai Life Sciences has only been the subject of 3 research reports in the past 90 days.

3.0

Short Interest

Percentage of Shares Shorted
4.81% of the float of Atai Life Sciences has been sold short.
Short Interest Ratio / Days to Cover
Atai Life Sciences has a short interest ratio ("days to cover") of 3.2, which is generally considered an acceptable ratio of short interest to trading volume.
Change versus previous month
Short interest in Atai Life Sciences has recently increased by 6.53%, indicating that investor sentiment is decreasing significantly.

0.0

Dividend Strength

Dividend Yield
Atai Life Sciences does not currently pay a dividend.
Dividend Growth
Atai Life Sciences does not have a long track record of dividend growth.

N/A

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
There is no current Upright™ data available for ATAI.

3.8

News and Social Media Coverage

News Sentiment
Atai Life Sciences has a news sentiment score of 0.81. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.53 average news sentiment score of Medical companies.
News Coverage This Week
MarketBeat has tracked 6 news articles for Atai Life Sciences this week, compared to 2 articles on an average week.
Search Interest
25 people have searched for ATAI on MarketBeat in the last 30 days. This is an increase of 19% compared to the previous 30 days.
MarketBeat Follows
22 people have added Atai Life Sciences to their MarketBeat watchlist in the last 30 days. This is an increase of 450% compared to the previous 30 days.

2.5

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Atai Life Sciences insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $164,742.00 in company stock.
Percentage Held by Insiders
30.00% of the stock of Atai Life Sciences is held by insiders. A high percentage of insider ownership can be a sign of company health.
Percentage Held by Institutions
Only 28.41% of the stock of Atai Life Sciences is held by institutions.

0.6

Earnings and Valuation

Earnings Growth
Earnings for Atai Life Sciences are expected to grow in the coming year, from ($0.80) to ($0.77) per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of Atai Life Sciences is -6.59, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of Atai Life Sciences is -6.59, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Book Value per Share Ratio
Atai Life Sciences has a P/B Ratio of 1.30. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

Ad InvestorPlace

You’re invited: Biggest crypto event of 2024

During the event on Tuesday, April 23 at 10 am ET, I’ll be giving away the name and ticker symbol of crypto that could surge in price. I believe it will be the best performing crypto of 2024.

Just click here to sign up and be among the first to get it.

About Atai Life Sciences Stock (NASDAQ:ATAI)

ATAI Life Sciences N.V., a clinical-stage biopharmaceutical company, engages in acquiring, incubating, and developing various therapeutics to treat depression, anxiety, addiction, and other mental health disorders. Its principal clinical programs include RL-007, a pro-cognitive neuromodulator for cognitive impairment associated with schizophrenia; GRX-917, a deuterated etifoxine for anxiety disorders; VLS-01 a N,N-Dimethyltryptamine for treatment resistant depression (TRD); DMX-1002, an oral formulation of ibogaine, a cholinergic, glutamatergic and monoaminergic receptor modulator that is a naturally occurring psychedelic product isolated from a West African shrub for the treatment of opioid use disorders (OUD); and EMP-01, an oral formulation of an MDMA derivative being developed for the treatment of post-traumatic stress disorder. The company's other clinical programs comprise PCN-101, a subcutaneous formulation of R-ketamine, as a therapy for psychiatric indications initially focused on TRD; and KUR-101, a formulation of deuterated mitragynine for the treatment of OUD. ATAI Life Sciences N.V. was founded in 2018 and is headquartered in Berlin, Germany with offices in New York and London.

ATAI Stock Price History

30 days | 90 days | 365 days | Advanced Chart

ATAI Stock News Headlines

April 18, 2024 | stockhouse.com

atai Life Sciences Announces the Publication of Beckley Psytech's Phase 1 Study of BPL-003 in the Journal of Psychopharmacology

April 18, 2024 | investing.com

atai Life Sciences reports positive Phase 1 results for BPL-003

April 19, 2024 | InvestorPlace (Ad)

You’re invited: Biggest crypto event of 2024

During the event on Tuesday, April 23 at 10 am ET, I’ll be giving away the name and ticker symbol of crypto that could surge in price. I believe it will be the best performing crypto of 2024.

April 17, 2024 | finance.yahoo.com

atai Life Sciences Announces the Publication of Beckley Psytech’s Phase 1 Study of BPL-003 in the Journal of Psychopharmacology

April 17, 2024 | proactiveinvestors.com

atai announces publication of Beckley Psytech's Phase 1 study for novel 5-MeO-DMT asset

April 17, 2024 | msn.com

Atai Life Sciences N.V. (ATAI) Price Target Decreased by 15.35% to 10.90

April 15, 2024 | proactiveinvestors.com

atai Life Sciences CEO Florian Brand spotlights psychedelic therapy milestones and upcoming catalysts

April 6, 2024 | investing.com

Atai Life Sciences executive sells $114k in company stock

April 19, 2024 | InvestorPlace (Ad)

You’re invited: Biggest crypto event of 2024

During the event on Tuesday, April 23 at 10 am ET, I’ll be giving away the name and ticker symbol of crypto that could surge in price. I believe it will be the best performing crypto of 2024.

April 4, 2024 | msn.com

Are You Looking for a Top Momentum Pick? Why atai Life Sciences N.V. (ATAI) is a Great Choice

April 3, 2024 | msn.com

Atai Life Sciences upgraded at Maxim on Beckley investment

April 2, 2024 | msn.com

UT Tyler University Academy senior directs first student-led theater production

April 1, 2024 | msn.com

Could We Ever Have Sci-Fi Tech Like the ‘Star Trek’ Transporter? A New Roddenberry Entertainment Podcast Finds Out

April 1, 2024 | finance.yahoo.com

Atai Life Sciences Full Year 2023 Earnings: EPS Beats Expectations, Revenues Lag

March 29, 2024 | msn.com

Atai Life Sciences Q4 And Full-Year 2023 Results: Steep Cash Drain Yet 2026 Target Remains, Update On Psychedelic Pipeline

March 28, 2024 | msn.com

Intranasal 5-MeO-DMT Clinical Trial Offers Hope For Treatment-Resistant Depression

March 28, 2024 | benzinga.com

Recap: ATAI Life Sciences Q4 Earnings

March 28, 2024 | proactiveinvestors.com

atai Life Sciences funded into 2026; sets sights on key milestones for its psychedelic therapies

March 28, 2024 | msn.com

ATAI Life Sciences GAAP EPS of -$0.12 beats by $0.04

March 28, 2024 | globenewswire.com

atai Life Sciences Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate and Clinical Highlights

March 27, 2024 | proactiveinvestors.com

atai-backed Beckley Psytech unveils positive results from DMT for treatment-resistant depression study

March 27, 2024 | markets.businessinsider.com

Atai Life: Beckley Psytech's Phase 2a Trial Of BPL-003 Positive In Treatment Resistant Depression

March 27, 2024 | finance.yahoo.com

atai Life Sciences Announces Positive Initial Results from Beckley Psytech’s Phase 2a Open Label Study of BPL-003 (Intranasal 5-MeO-DMT) in Treatment Resistant Depression

March 27, 2024 | globenewswire.com

atai Life Sciences Announces Positive Initial Results from Beckley Psytech's Phase 2a Open Label Study of BPL-003 (Intranasal 5-MeO-DMT) in Treatment Resistant Depression

March 15, 2024 | morningstar.com

Thinking about buying stock in Lexicon Pharmaceuticals, Cassava Sciences, Clearside Biomedical, Lantern Pharma, or ATAI Life Sciences?

March 14, 2024 | finance.yahoo.com

Caris Life Sciences to Showcase Research at 2024 SGO Annual Meeting on Women's Cancer

March 14, 2024 | msn.com

Psychedelic drug ibogaine hailed as healing. U.S. patients ask why it’s illegal.

See More Headlines

Receive ATAI Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Atai Life Sciences and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings: 8/10/2023
Today: 4/18/2024
Next Earnings (Estimated): 5/09/2024
Fiscal Year End: 12/31/2024

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Sector: Medical
Industry: Pharmaceutical preparations
Sub-Industry: N/A
Current Symbol: NASDAQ:ATAI
CUSIP: N/A
CIK: 1420529
Web: www.atai.net.cn
Phone: 49-89-2153-9035
Fax: N/A
Employees: 133
Year Founded: N/A

Price Target and Rating

Average Stock Price Target: $10.50
High Stock Price Target: $15.00
Low Stock Price Target: $6.00
Potential Upside/Downside: +449.7%
Consensus Rating: Buy
Rating Score (0-4): 3.00
Research Coverage: 3 Analysts

Profitability

EPS (Most Recent Fiscal Year): ($0.29)
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-40,220,000.00
Net Margins: -12,810.51%
Pretax Margin: -12,511.46%
Return on Equity: -45.08%
Return on Assets: -38.46%

Debt

Debt-to-Equity Ratio: 0.08
Current Ratio: 9.22
Quick Ratio: 9.22

Sales & Book Value

Annual Sales: $310,000.00
Price / Sales: 1,022.96
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: $1.47 per share
Price / Book: 1.30

Miscellaneous

Outstanding Shares: 166,030,000
Free Float: 116,218,000
Market Cap: $317.12 million
Optionable: Optionable
Beta: 0.98

12 Stocks Corporate Insiders are Abandoning

If a company's CEO, COO, and CFO were all selling shares of their stock, would you want to know?

Get This Free Report

Key Executives

Mr. Christian Angermayer (Age 46)
Founder & Chairman of the Supervisory Board
Comp: $70k
Mr. Florian Brand (Age 37)
Co-founder & CEO
Comp: $835.44k
Dr. Srinivas G. Rao M.D. (Age 55)
Ph.D., Co-Founder & Chief Scientific Officer
Comp: $834.15k
Mr. Stephen B. Bardin (Age 33)
Advisor
Comp: $651.32k
Ms. Anne Johnson
Chief Financial Officer
Dr. Michael Raven Ph.D.
Senior Vice President of Operations
Mr. Frank Stegert (Age 43)
Vice President of Investment & Venture Management
Mr. Ryan Barrett (Age 43)
Senior VP, General Counsel & Corporate Secretary
Dr. Glenn Short Ph.D.
Senior Vice President of Early Development
Dr. Sahil V. Kirpekar M.D. (Age 38)
Chief Business Officer

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions

ATAI Stock Analysis - Frequently Asked Questions

Should I buy or sell Atai Life Sciences stock right now?: 3 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Atai Life Sciences in the last twelve months. There are currently 3 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" ATAI shares.
View ATAI analyst ratings or view top-rated stocks.
What is Atai Life Sciences' stock price target for 2024?: 3 Wall Street analysts have issued 1-year target prices for Atai Life Sciences' stock. Their ATAI share price targets range from $6.00 to $15.00. On average, they anticipate the company's stock price to reach $10.50 in the next twelve months. This suggests a possible upside of 449.7% from the stock's current price.
View analysts price targets for ATAI or view top-rated stocks among Wall Street analysts.
How have ATAI shares performed in 2024?: Atai Life Sciences' stock was trading at $1.41 at the start of the year. Since then, ATAI stock has increased by 35.5% and is now trading at $1.91.
View the best growth stocks for 2024 here.
Are investors shorting Atai Life Sciences?: Atai Life Sciences saw a increase in short interest in March. As of March 31st, there was short interest totaling 5,550,000 shares, an increase of 6.5% from the March 15th total of 5,210,000 shares. Based on an average daily volume of 1,740,000 shares, the short-interest ratio is presently 3.2 days. Approximately 4.8% of the company's shares are sold short.
View Atai Life Sciences' Short Interest.
When is Atai Life Sciences' next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Thursday, May 9th 2024.
View our ATAI earnings forecast.
How were Atai Life Sciences' earnings last quarter?: Atai Life Sciences (NASDAQ:ATAI) posted its quarterly earnings data on Thursday, August, 10th. The company reported ($0.21) earnings per share (EPS) for the quarter, meeting the consensus estimate of ($0.21). The company had revenue of $0.17 million for the quarter. Atai Life Sciences had a negative net margin of 12,810.51% and a negative trailing twelve-month return on equity of 45.08%.

What ETF holds Atai Life Sciences' stock?: AdvisorShares Psychedelics ETF holds 187,558 shares of ATAI stock, representing 5.86% of its portfolio.
What other stocks do shareholders of Atai Life Sciences own?: Based on aggregate information from My MarketBeat watchlists, some companies that other Atai Life Sciences investors own include Alphabet (GOOG), Baidu (BIDU), Costco Wholesale (COST), MannKind (MNKD), NVIDIA (NVDA), Schlumberger (SLB), Twitter (TWTR), Adobe (ADBE), Allergan (AGN) and Achaogen (AKAO).
When did Atai Life Sciences IPO?: Atai Life Sciences (ATAI) raised $200 million in an initial public offering on Friday, June 18th 2021. The company issued 14,300,000 shares at a price of $13.00-$15.00 per share. Credit Suisse, Citigroup, Cowen and Berenberg acted as the underwriters for the IPO and Cantor, RBC Capital Markets and Canaccord Genuity were co-managers.
Who are Atai Life Sciences' major shareholders?: Atai Life Sciences' stock is owned by many different institutional and retail investors. Top institutional investors include Quattro Financial Advisors LLC (0.04%), Kingswood Wealth Advisors LLC (0.02%) and CRA Financial Services LLC (0.01%). Insiders that own company stock include Anne Nagengast Johnson, Apeiron Investment Group Ltd, Christian Angermayer, Florian Brand, Gregory L Weaver and Srinivas Rao.
View institutional ownership trends.
How do I buy shares of Atai Life Sciences?: Shares of ATAI stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:ATAI) was last updated on 4/19/2024 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial

Atai Life Sciences (ATAI) Stock Price, News & Analysis

Atai Life Sciences MarketRank™ Stock Analysis

Overall MarketRank™

Analyst's Opinion

Short Interest

Percentage of Shares Shorted

Short Interest Ratio / Days to Cover

Change versus previous month

Dividend Strength

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score

News and Social Media Coverage

News Sentiment

News Coverage This Week

Search Interest

MarketBeat Follows

Company Ownership

Earnings and Valuation

About Atai Life Sciences Stock (NASDAQ:ATAI)

ATAI Stock Price History

ATAI Stock News Headlines

Company Calendar

Industry, Sector and Symbol

Price Target and Rating

Profitability

Debt

Sales & Book Value

Miscellaneous

Key Executives

Key Competitors

Insiders & Institutions

ATAI Stock Analysis - Frequently Asked Questions

Overall MarketRank^™